Should I buy Labcorp (LH) stock or is it too late?

Labcorp · Health Care · price $337

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $338 (+0.4 %), call made on August 1, 2026, maturing on August 1, 2027 (27 d ago).

The 7 reliable analysts $338+0.4 %

The 1 other firm $300-11 %

How to read it: the 7 reliable firms are not filtered by optimism — 4 aim above the price, 3 below, hence their $338 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Labcorp

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	100 %	+33.3 %	5	$360 +7%
UBS	90 %	+22.2 %	10	$320 -5%
Citigroup	100 %	+19.4 %	5	$300 -11%
B of A Securities	83 %	+17.4 %	6	$320 -5%
Barclays	67 %	+17.1 %	9	$320 -5%
Baird	86 %	+13.9 %	14	$338 +0%
Deutsche Bank	71 %	+11.3 %	7	$230 -32%
Morgan Stanley	70 %	+9.6 %	23	$338 +0%

In short — Should you invest in Labcorp? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $329, i.e. -2%), and the most reliable on LH targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
The most reliable firm on LH, JP Morgan (100% hit rate, 5 scored calls), targets $360 (call made on August 3, 2026, maturing on August 3, 2027) (+7%) in its most recent call, and $317 (call made on November 7, 2025, maturing on November 7, 2026) (-6%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 2 are neutral.
Limited upside: the median target is only -2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on LH

Median target $329 (-2%) · 8 ratings · Buy consensus

Strong Buy00%

Buy675%

Hold225%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Labcorp now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $329 (-2%), and JP Morgan (most reliable on LH, 100%) targets $360. Weigh that against valuation (P/E ~28). This is not personalized advice.

Is it too late to invest in Labcorp?

The stated upside is small: the median target ($329) sits just -2% from the price ($337) (most reliable on LH: JP Morgan, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Labcorp still worth investing in?

It depends on the gap between the price ($337) and its estimated value: analysts target $329 on median (-2%), with 75% buys (most reliable on LH: JP Morgan, 100%). Cross-check with their real reliability on LH and the cautions above. Information, not advice.

What's the main risk in buying LH?

The consensus is not unanimous: of 8 ratings, 2 are neutral.

→ Go deeper: the full Labcorp profile (consensus, analyst reliability, price target, performance).